Munich Leukemia Laboratory, a leukemia and lymphoma diagnostic and research lab in Germany, has joined forces with IBM and Illumina.
The Munich Leukemia Laboratory researchers will use Illumina's NovaSeq technology to sequence samples from its biobank of more than 500,000 cases. After sequencing, the researchers will use IBM's Watson system to analyze this genomic data in an effort to develop personalized leukemia treatments.
The ultimate goal of the project is to develop a Watson-based prototype that can analyze genomic and phenotypic data to provide clinicians with decision support related to leukemia care.
"We at MLL are excited to combine our data and knowledge, IBM's cognitive computing tools and Illumina's new sequencing platform to create a new era of insights in leukemia biology that will also drive more personalized treatment strategies," said Dr. Torsten Haferlach, cofounder and CEO of the Munich Leukemia Laboratory.